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ABSTRACT

The objective of this work was to determine what cellular factor or factors are
related to the tumorigenicity of certain glioma tumor cell lines. The study of the growth
characteristics of this tumor type is of particular interest considering that a primary
factor in its malignancy is the impinging damage it causes by growing in the confined
space of the cavernum.
The correlation of tumorigenicity with ability to proliferate, or "clone", while
suspended in a semi-solid medium has been well documented for many types of cell
lines, including gliomas. Following this precedent, a successful correlation between
tumorigenicity and clonigencity was demonstrated for the glioma cell lines studied in
this investigation. Likewise, non-clonigenic cell lines were unable to form tumors in
nude mice. Also of interest was one cell line that was essentially non-clonigenic, but
formed tumors that completely regressed after approximately two weeks.
Having established the correlation between clonigenicity and tumorigenicity,
the next objective was to create a cDNA expression library from the tumorigenic
glioma cell line. This was partially completed at the time of the termination of the
research year. The future plan for this library, once completed, is to introduce it into a
non-tumorigenic, non-clonigenic cell line and select for transformants that could clone
in soft agar. These clonigenic transformants would then be further selected for
tumorigenicity in nude mice, and the transforming cDNA recovered and characterized.
The identification of the transforming element would aid in understanding the
formation of glioma tumors and add further insight into the enigma that is cancer.

INTRODUCTION
Since antiquity, the spectrum of diseases that we generalize as cancer has
mystified mankind. Recent advances in science, in particular molecular biology, have
exponentially accelerated our quest to understand this enigma and come closer to
conquering diseases of uncontrolled cell growth. The research presented in this work
has utilized the tools of molecular biology to probe the questions surrounding
abnormal cell growth and differentiation of a particular type of cancer, the human
glioma.
The human glioma is the most common intracranial brain neoplasm in adults,
representing approximately 35% or more of human intracranial tumors (Zulch, 1986).
Glial tumors, such as astrocytomas, ependymomas, oligodendrogliomas, and
glioblastomas, are derived from a variety of glial cell types of neuroectodermal origin.
Histopathalogically they have been classified into four grades of malignancy, the most
malignant being the glioblastoma multiforme, with a five year post-operative survival
rate of <5%, regardless of adjuvant radiation therapy or chemotherapy (Burger, et al.,
1985).
Models of Oncogenesis:
Recent evidence has suggested that gliomas evolve through a succession of
stages of increasing malignancy, with the endpoint being the glioblastoma multiforme.
James, et al. (1988) examined glial tumor tissue of varying histological malignancy
grade and found that 28 of 29 tumors classified as glioblastoma (grade IV)
demonstrated a loss of constitutional heterozygosity for loci on chromosome 10,
whereas all 22 glial tumors of lower malignancy grade revealed no such loss.
Restriction fragment length polymorphism analysis on the other chromosomes
demonstrated that chromosomes 13, 17, and 22 had deletions at nonrandom
frequencies (14, 22, and 19%, respectively) and each occurred in at least one case of
each malignancy grade of glioma, in contrast to the grade IV specific loss of
chromosome 10 . These authors postulate a progressional model for grade IV gliomas
in which the glial malignancy undergoes a variety of chromosomal aberrations
preceding a loss of chromosome 10 and evolution to glioblastoma:
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A. Precursor Cell (type 1) — Grade II — Grade III
Precursor Cell (type 2) — Grade IV (glioblastoma)
B. Precursor Cell — Grade II — Grade III -*■ Grade IV (glioblastoma)
C. Precursor Cell — Grade II — Grade III
OR
— Grade IV (glioblastoma)
D. Precursor Cell -> Grade II -*• Grade III

Grade IVA (glioblastoma)

OR — Grade IVB (glioblastoma)
Model A proposes that a different precursor cell would lead to the formation of a
glioblastoma than would lead to lower grade astrocytomas. Model B proposes that
glioblastomas arise from malignant evolution from a single precursor cell. Model C
proposes that a single precursor cell may undertake two different pathways, one
leading to glioblastoma formation, and the other to the development of a lower grade
malignancy. Model D recognizes that there is evidence that some glioblastomas may
arise spontaneously, for example, those with normal genotypes or 45 X,0, thus having
no indication of progressive chromosomal alteration. This model proposes that there
may be two routes to glioblastoma formation: spontaneous and progressive.
Bigner et al. (1988) also have reported specific chromosomal abnormalities in
malignant human gliomas. In their study of 54 gliomas of varying types (5 anaplastic
astrocytomas, 43 glioblastomas, 3 gliosarcomas, 2 giant cell glioblastomas, 1
anaplastic mixed glioma), they observed that 4 of the 5 anaplastic astrocytomas, a
lower histopathalogic grade than glioblastomas, had either normal karyotypes or only
lacked one gonosome. Of all the malignant human glioma types studied, including
glioblastomas, 32 had abnormal stemline karyotypes in the near-diploid range. Gains
of chromosome 7 occurred in 26 of these, and losses of chromosome 10 occurred in
19. Double minutes (DM) occurred in 18 of the 32 gliomas with near-diploid
stemlines, and chromosomal breaks in 9p and 19q reached statistical significance.
In this study, glioblastomas exhibited a variety of chromosomal aberrations. Of
the 43 glioblastomas studied, 8 had either normal karyotypes or were 45 X,0. There
were 27 glioblastomas with near-diploid karyotypes; of these, two could not be fully
characterized karyotypically. Of the remaining 25 near-diploid glioblastomas, 18 had
2

a loss of chromosome 10, 20 had a gain of either part or an entire chromosome 7, and
17 had both these anomalies. Additionally, 8 of the 43 glioblastomas were neartriploid or near-tetraploid.
These authors suggest that the chromosomal +7, -10, and DM anomalies
represent the earliest gross chromosomal aberrations in near-diploid malignant
human gliomas, since these aberrations occurred in high frequency in their study and
there were tumors that demonstrated these and no other chromosomal anomalies (2
glioblastomas, 1 gliosarcoma). This is in contrast to the proposal of James, et al.
(1988), who postulate that loss of chromosome 10 is a later event in a succession of
chromosomal aberrations that cause increasing malignancy in gliomas.
Proto-oncogene Expression in Gliomas:
Epidermal growth factor receptor:
There have been many reports in the literature regarding the expression of a
variety of growth factor and receptor types in human gliomas. The over-expression of
the receptor for epidermal growth factor (EGF-R), has been among the most frequently
reported. EGF-R is a cell surface receptor which possesses tyrosine kinase activity
(Ushiro, et al., 1980), and is the cellular homologue of the viral oncogene erbB
(Downward, et al., 1984). It has been mapped to chromosome 7 of the human
genome (Spurr, etal., 1984).
Libermann et al. (1985) have demonstrated that 4 of 10 glioblastomas studied
contained amplified copies of the EGF-R gene in the range of 6-60 fold greater than
normal. Additionally, two of these were further studied and found to have novel
restriction fragment patterns which suggest rearrangement of that gene. Gerosa, et al.
(1989) have also demonstrated this phenomenon, with 4 of 5 primary cell lines and 5
of 5 tumor specimens exhibiting overexpression of the EGF-R gene. In three of these
cases there was a concomitant increase in copies of chromosome 7, but the EGF-R
gene expression was greater than expected when taking this into consideration. This
suggested that some loss of control of transcriptional activity of the gene had also
occurred.
In other malignant cell types that exhibit increased expression of EGF-R, such
as the human epidermoid carcinoma cell line A431, it has been demonstrated that
there is a variable growth response to the EGF-R ligand, EGF. In cells that have 105
or fewer receptors per cell, 1-3.4 nM concentrations of EGF result in growth stimulation
3

or no change in growth, whereas cells that have receptor numbers approaching 106
per cell or greater are growth inhibited by EGF (Kawamoto, et al., 1984). Werner, et al.
(1988), studied the effect of EGF on four glioma cell lines with elevated EGF-R
expression and demonstrated that one glioma cell line with a high number of EGF-R
receptors (approaching 106 or greater) was growth inhibited by 3.3 nM EGF, while two
cell lines with 105 or fewer EGF-R per cell were growth stimulated or had no response.
Interestingly, another cell line with 1.59X106 receptors per cell was growth stimulated
by EGF, seeming to contradict previous observations made between the inverse
relationship between receptor number and growth response.

It is believed, however,

that the EGF-R gene in that cell line may be rearranged and autophosphorylates at an
abnormally low level. The cell line, therefore, would then behave as if it had a lower
number of fully active receptors. The variable response observed by these authors
may indicate that there exists a threshold for growth stimulation by EGF. Cell lines that
express receptor numbers in the range of 106 or greater become growth inhibited
possibly due to depletion of intercellular energy stores or other undefined inhibitory
pathways (Werner, et al., 1988).
Despite the documentation of elevated expression of the EGF-R gene in
gliomas in the above and other references (Wong et al, 1987; Filmus, et al., 1985), it
remains unclear if there is a causal relationship between this and malignant properties
of gliomas. Wells, et al. (1988) have demonstrated that human glioblastoma cell line
SF268 overexpresses the EGF-R gene, but its product is an enzymatically inactive
protein, pointing to a different mechanism of altered cell growth in that cell line.
Gerosa, et al. (1989) documented primary glioma cell lines that overexpress EGF-R
with concomitant overexpression of N-ras, an oncogene which exhibits intrinsic
guanosine triphosphatase activity (Levinson, 1986), as well as overexpression of
TGFa, a growth factor that also binds to and activates the EGF receptor (Schreiber, et
al., 1986). They propose that these three factors act in concert to confer uncontrolled
growth characteristics in malignant gliomas, since activation of EGF-R has been
shown previously to stimulate both the guanine nucleotide binding activity and
phosphorylation of ras oncogene proteins (Kamata & Feramisco, 1984), and the N-ras
protein has been shown to couple growth factor receptors to inositol phosphate
production (Wakelam, et al., 1986).
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Platelet-derived growth factor:
Human platelet-derived growth factor is mitogenic for cells of mesenchymal
origin (Ross, et al. 1986). It exists as a homo- or heterodimer of two related
polypeptide chains, A and B, which are each the product of a distinct cellular gene
(Johnsson, et al., 1982); the gene for PDGF-A has been mapped to chromosome 7
(Betsholtz, et al. 1986), and the gene for PDGF-B to chromosome 22 (Dalla Favera, et
al. 1982). PDGF-B has been shown to be the cellular analogue to the v-sis oncogene
(Doolittle, et al., 1983).
PDGF-A and PDGF-B have been shown to have different properties. Beckmann
et al. (1988) transfected NIH 3T3 cells with plasmids carrying the gene for each of
these, and showed that the cells transfected with PDGF-B had a 20 fold or greater
transforming efficiency and formed larger, more aggressive foci than those cells
transfected with the PDGF-A gene. The product of the PDGF-A gene was found to be
actively secreted by the transfected cell such that the cell culture medium was
mitogenic with 70% to 80% of the total PDGF-A synthesized in a 3 hour period was
released. This contrasts with the product of the PDGF-B gene which was undetected
in tissue culture fluids. These authors suggest that PDGF-A may have a primary role in
stimulating cell proliferation at a distance, whereas PDGF-B may exhibit only autocrine
or paracrine effects.
Nister, et al. (1988) have demonstrated that 10 of 14 glioma cell lines studied
expressed mRNA from both the PDGF receptor gene and one or both of the PDGF
genes. (Additionally, 11 of the 14 expressed mRNA from both the EGF-R gene and
one of its ligands, TGFa .) These authors postulate that these observations may
indicate the presence of autocrine receptor stimulation which confers independence
from exogenous growth factors on cultured cells and possibly points toward a key
event in tumorigenesis. Their additional observation that receptor blocking monoclonal
antibodies to the PDGF receptor, EGF-R, or both concomitantly, did not produce
marked or consistent growth inhibition is explained by considering the existence of an
intracellular autocrine loop to be an early event in giioma development.

Once a

selective growth advantage is conferred by this mechanism, a subsequent event
overrides the need for autocrine simulation, such as amplification of the c-myc gene
which has been shown to lessen cell dependence on PDGF (Armelin, et al., 1984).
Thus, a cell line once dependent on autocrine production of growth factor for selective
growth advantage can evolve to complete growth factor independence. This proposal
may be further supported by the observations of Fujimoto, et al. (1988) who found that
5

a v-myc probe had 4 to 12-fold greater hybridization to the mRNA from glioblastomas
as compared to more benign tumors such as the cystic cerebellar astrocytoma or the
ganglioglioma.
Other proto-oncoaene expression in gliomas:
In addition to the above, there have been numerous reports of other cellular
proto-oncogenes expressed in gliomas. Heisterkamp, et al. (1990) have reported a
glioblastoma cell line which expresses a rearranged abl gene, more commonly
associated with the Philadelphia chromosome and chronic myelogenous leukemia. In
contrast to the bcr-abl rearrangement in the Philadelphia chromosome which occurs at
the 5’ end of the gene, the rearrangement of abl in the glioblastoma occurred at the 3’
end of the gene resulting in the expression of truncated mRNA transcripts. Since no
normal abl transcripts were produced by the cell line in question, the authors suggest
the possibility that a complete absence of normal abl expression may have contributed
to the tumorigenesis of the glioblastoma, although they do not discount that this
rearrangement may have occurred in vitro independent of the malignant progression
of the original tumor.
Birchmeier, et al. (1987) demonstrated in glioblastomas expression of the
transcripts for ros I, which is closely related to EGF-R. Of 9 glioblastoma cell lines and
tissue samples, 5 showed a 10 to 60-fold increase in ros I transcripts as compared to a
control. Normal glial tissue had no detectable ros I expression The expression of ros I
seemed to be specific to glial brain neoplasms, since a broad survey of other solid
tumor types including carcinoma of the breast and bladder, Wilm’s tumor of the kidney,
neuroblastoma, as well as leukemia and lymphoma failed to show any expression of
the ros I gene. In one of the glioblastomas studied, the ros I gene was shown to be
both rearranged and overexpressed. These authors postulate a role of ros I in the
development of glial neoplasms, given that it is a potential oncogene that is not
expressed by normal tissue and its expression seems to be specific to glioblastomas.
Blin et al. (1987) have described a human glioblastoma cell line that has
nullisomy 13 and overexpression of abl, erbB, myc and Ha-ras. This overexpression
could not be demonstrated to result from the frequently observed mechanisms of gene
amplification or rearrangement of the loci. The homozygous deletion of part of
chromosome 13 had been previously shown to be correlated with the oncogenesis of
the retinoblastoma (Cavenee, et al., 1983) and the overexpression of N-myc in that
neoplasm (Lee, et al., 1984). The deleted portion of chromosome 13 encodes an
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"anti-oncogene" which regulates the expression of N-myc in normal tissue, and its
absence allows uncontrolled transcription of this gene (Knudson, 1985; Xu, et al. ,
1989). The authors postulate that a similar mechanism of oncogenesis may occur in
glioblastomas where nullisomy 13 would contribute uncontrolled expression of abl,
erbB, myc and Ha-ras and confer malignant characteristics upon the cell.
Experimental Objective:
The human glioma is a useful and interesting system to investigate
tumorigenicity given its undetermined mechanism of malignant development as well
as the aggressiveness of the grade IV glioma, the glioblastoma. Elucidation of the
mechanism by which the glioblastoma develops presumably from lower grade
astrocytomas would not only give us insight into a particularly lethal neoplasm, but
perhaps could be extrapolated to other neoplastic systems, giving us a better
understanding of cancer in general.
The objective of this project was to determine what factor or factors are related
to the tumorigenicity of established glioma cell lines. The initial step would be to
correlate cell line tumorigenicity (i.e., growth in athymic "nude" mice), a property of
more aggressive malignancies, with an in vitro growth property to be able to
effectively and efficiently screen cell lines for tumorigenic potential.
Malignant changes in cells confer multiple in vitro properties that make the cells
resistant to environmental factors that generally restrict growth in normal cells. Among
these are the ability to grow in culture in low serum concentration (Dulbecco, 1970),
lack of contact inhibition (Todaro & Green, 1963), and lack of dependence on solid
surface for anchorage (MacPherson & Montagnier, 1964). To date, anchorageindependent growth, defined as cell proliferation when deprived of attachment to the
tissue culture plate, remains the most reliable in vitro correlate of the ability of a cell to
form tumors in athymic "nude" mice (Freedman & Shin, 1974). Thus, the initial step in
this investigation was to demonstrate the correlation between anchorage-independent
growth (i.e., "cloning in soft agar", "clonigenicity") and the ability to form tumors in nude
mice.
Once this correlation was established, a cDNA expression library was to be
made from a highly clonigenic/ tumorigenic cell lines and transfected into a nonclonigenic/non-tumorigenic cell line. By such transfection, a gene associated with
malignant phenotype of the clonigenic/ tumorigenic cell line could be introduced into
the non-clonigenic/non-tumorigenic cell line.
7

This could confer transformation of the

non-clonigenic/ non-tumorigenic cell line to a more malignant phenotype that exhibits
clonigenic and tumorigenic properties. Transformed cell lines could be screened by
growth in soft agar, and cell lines could be established from any cells that form
colonies. The cell line would then be introduced into nude mice to reconfirm the
associated properties of clonigenicity and tumorigenicity. The transforming cDNA
could be recovered and analyzed to determine what factor(s), whether known or novel,
conferred tumorigenicity.
In conjunction with the above, additional questions were also asked. For
example, what known factors associated with clonigenicity and tumorigenicity are
produced by the cell lines in question? This could be determined by probing the
mRNA from each cell line with relevant cDNA probes. Also, did clonigenic/tumorigenic
cell lines produce an excretable mitogen that could be harvested from culture medium
and induce transformation of non-clonigenic/non-tumorigenic cell lines? The
occurrence of this may provide further support for the existence of an autocrine or
paracrine loop as a means of growth factor independence and uncontrolled
proliferation. Also, this could give insight into the progressional development of
gliomas. For example, non-clonigenic/non-tumorigenic cell line may have a receptor
for this factor but be unable to produce it in significant quantities to bring about a more
malignant phenotype, thus being in an earlier stage of oncogenesis. The
experimental protocol is outlined in Figure 1.
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FIGURE 1

An outline of experimental protocol. The construction
of the cDNA library is the current point of this investigation.

9

IDENTIFY

CLGNIGENIC,

NON-CLONIGENIC,

TUMORIGENIC
and
NON-TUMORIGENIC

CELL

LINE

\

\

/

Is a diffusable factor produced by the
tumorigenic, clonigenic cell line that
could induce clonigenicity in a
non-clonigeni c
cell line?

Which of the growth factors known
to be associated with clonigenicity
are produced by the cell lines
in question?

I

^
^

LINE

\

/
/

▼

CELL

PREPARE

CELLULAR
RNA

"

Northern blot analysis for
growth factor gene expression
''

ISOLATE POLY A RNA FROM CLONIGENIC, TUMORIGENIC
CELL LINE AND MAKE A cDNA EXPRESSION LIBRARY

TRANSFECT LIBRARY INTO NON-CLONIGENIC,
NON-TUMORIGENIC CELL LINE

’

r

SELECT TRANSFORMANTS FOR ABILITY TO CLONE IN SOFT
AGAR, TO FORM TUMORS IN NUDE MICE

''

RETRIEVE

TRANSFECTED

cDNA

AND

CHARACTERIZE

MATERIALS & METHODS:

Enzymes and Chemicals:

Restriction endonucleases and DNA polymerases were obtained from New
England Biolabs, Bethesda Research Laboratories, or IBI. T4 DNA ligase was
obtained from IBI. Restriction endonuclease and ligation buffers were obtained in 10X
concentration from the above companies. A Not I linker was obtained from New
England Biolabs. All other chemicals were reagent grade.
Media:

Bacterial cultures were grown in LB enriched medium supplied by the NIH.
Glioma cell cultures were grown in RPMI 1640 with 10% fetal calf serum/ 3 mM
glutamine/ lOOU/ml penicillin G and 12.5 pg/ml streptomycin sulfate. Fetal calf serum
of the same manufacturer lot number was used for all experiments to protect against
variability of growth factors and mediators found in different lots.
Cell Lines:

The glioma cell lines studied were originally established by Bigner, et al.
(1981), and were brought up from frozen stock present in the laboratory of Dr. Mark
Israel with preparation dates and passage numbers as indicated. Cell lines U251mgSF and U343mgA-SF were the gift of Dr. Michael Behrens of the University of
California at San Francisco. Glial fibrillary acidic protein (GFAP) expression, a glial
cell specific marker, is as follows:
cell line:
U251mg-SF
U251mg-NIH
U373mg
U118mg
U105mg
U343mg-NIH
U343mgA-SF

number of passaaes

oriqin

436
250 (approx.)

glioblastoma multiforme

GFAP
+

glioblastoma multiforme

unknown

186
470

glioblastoma multiforme

unknown

anaplastic glioma

39
44

glioblastoma multiforme
anaplastic glioma

433

anaplastic glioma

unknown
unknown
unknown
+

11

Bringing Up Cells From Frozen Stock:
To establish cultures from frozen cell stocks, the cells (stored at -70°C in 1 ml
aliquots) were thawed by swirling in a 37°C water bath. The cells were washed by
pipetting into a sterile tube containing 10 ml of cell culture medium and resuspending
by gentle shaking. After centrifuging at 1200 rpm for 3 minutes, the medium was
poured off, and the pellet resuspended in 5 ml of fresh medium. The cells were then
added to a sterile T150 cell culture flask (250 ml volume) containing 20 ml of cell
culture medium. The flask was then placed horizontally in a humidified 5% C02
incubator.
Maintenance of Cultured Cells:
Cell cultures were maintained by growing one or more T150 flasks to
confluency in a humidified 5% CO2 incubator with flask caps slightly loosened. Cell
cultures were fed every 3 to 7 days, or as required, by aspirating the old medium under
sterile conditions and pipetting into the flask 25 ml of fresh medium.
Confluent cell cultures were split by sterilely aspirating the cell culture medium,
rinsing the ceils with 5 ml of medium (without added fetal calf serum) and aspirating
the rinse medium. Five ml of Puck’s saline/1 mM EDTA was then added to the flask,
which was then placed horizontally so the confluent monolayer was in contact with the
solution, and the cells were allowed to loosen from the plastic. If the cells remained
adhered to the plastic, the flasks were then firmly hit on the side and/or incubated for
five to ten minutes in a 37°C incubator to encourage loosening. Once the cells were
suspended in the Puck’s saline solution, half of the suspension was pipetted out of the
flask and either discarded or pipetted into another flask if expansion of the cell line
was desired. Twenty-five ml of fresh medium was added to each flask, which was
then returned to the 37°C incubator.
Making -70°C Frozen Aliquots of Cultured Cells:
Cultured cell Sines were prepared for storage at -70°C in the following manner:
Three T150 cell culture flasks of the desired cell line were grown to confluency, the
cells being fed fresh medium the day prior to freezing. The medium was aspirated
from each flask and the cells were rinsed, then loosened from their growing surface
12

with Puck’s saline/1 mM EDTA as previously described. In a sterile hood, the cell
suspensions from each flask were consolidated into a sterile 10 ml conical tube and
centrifuged for five minutes at 1200 rpm. The supernatant medium was then poured
off, and the cell pellet resuspended in 8.1 ml of RPMI 1640 medium containing 10%
fetal calf serum. To this was added 0.9 ml DMSO. the suspension was mixed well by
drawing it in and out of a 10 ml sterile pipet. The cell suspension was then
immediately pipetted into screw-top Nunc tube in nine 1 ml aliquots. These were
placed vertically in a styrofoam container, and the container was placed in a -70°C
freezer overnight. The purpose of the styrofoam container was to partially insulate the
cell suspension, diminishing the formation of ice crystals within the cells. The
following day the aliquots were removed from the styrofoam container and place in a
designated storage area. The original T150 flasks could be refed and incubated if
desired.
Counting Cells:
Cultured cells were loosened from their flasks with 2 ml Puck’s saline/1 mM
EDTA as described above.

One ml of this suspension was removed and placed in a

sterile tube. (The remaining 1 mi of the cell suspension in the flask was refed with 25
ml of medium and returned to the incubator. ) From the 1 ml aliquot of cell
suspension, 10 to 15 pi of cell suspension was pipetted into a microcentrifuge tube
and an equal volume of bromphenol blue dye was added. This suspension was
mixed well by drawing it in and out of a pipet, the 15-20 pi was pipetted under a
coverslip into the reservoir on a hemacytometer. This caused a thin layer of cell
suspension to form by capillary action under the cover slip across the grid of the
hemocytometer. The hemocytometer was then viewed under a microscope. The
number of cells in each of nine fields was counted. The average of these numbers
was calculated and multiplyed by 2x104 to obtain the number of cells/ml. (The factor
104 corrects for the volume held by the hemocytometer and the factor 2 corrects for the
1:1 dilution of cell suspension with dye.) If the number of cells viewed by the
hemocytometer were too numerous to count, the original 1 ml aliquot was serially
diluted with culture medium to a concentration that was more manageable.
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Cloning in Soft Agar:

Tumor cell lines were suspended and grown in soft agar medium by a
modification of the method originally described by Macpherson and Montagnier
(1964):
Five media stock solutions having different final concentrations of fetal calf
serum were prepared (see Table 1). The agar underlay was prepared in the following
manner:
80 ml of the desired stock solution media was pipetted into a sterile 125 ml
bottle and placed in a 48°C heating block under a sterile hood for 5 to 10 minutes. To
this was added 20 ml of sterile, freshly autoclaved 2.5% agarose which was allowed
to equilibrate in a 60°C water bath for approximately 10 minutes prior to use. (The
agarose solution was made in 100 ml volumes in distilled, deionized water.) The
resultant medium/agarose solution ( still at 48°C in the heating block) was mixed by
drawing in and out of a pipet. The medium/agarose solution was then pipetted into
6-well cell culture plates at 4 ml per plate, with caution taken not to form any bubbles
on the surface of the agar. After hardening uncovered under the sterile hood, the
plates could be covered, wrapped in plastic wrap, and stored at 4°C until ready to use.
Before use, the plates were placed in a 37°C C02 incubator for at least 1 hour.
To prepare the overlay containing suspended cells, 80 ml of the desired stock
solution was pipetted sterilely into a 125 ml bottle and placed in a 48°C heating block
under a sterile hood. To this was added 10 ml of sterile water and 10 ml of sterile
2.5% agarose prepared as described above. After mixing well, 2 ml of the
medium/agarose solution was pipetted into a sterile capped tube (with a rounded, not
conical bottom) along with the desired number of cells. [Cells were prepared by
treating a confluent monolayer with 100 pi 0.05 pg/ml trypsin in 2 ml Puck’s saline/
1 mM EDTA and washing cells in serum-free medium as previously described,
resuspending in 1 ml medium with desired percentage of serum. Cell were counted
(see above), and appropriate dilutions were made with medium so that the desired
amount of cells could be added in a volume no greater than 200 pi.] The contents of
the tube were then vortexed briefly and quickly poured over the underlay. After
hardening under the sterile hood, they were placed in a 37°C, 5% CO2 incubator.
(See Figure 2.)
Soft agar cultures were allowed to incubate for 2-3 weeks, and the growth of
suspended cell colonies was monitered visually at 40X magnification. The
14

TABLE 1

Stock solutions of media for soft agar cloning.
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FIGURE 2
Method of soft agar cloning.
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SOFT

AGAR CLONING

UNDERLAY:

or:
oc
QC
RPMI 1640
♦ serum
0.5X agarose
48°C

chill 4°C to harden
incubate 37°C, 5X C02
until ready to use

6 well plate
pipette 4 ml/plate

OVERLAY:

♦ serum
0.25X agarose
48°C

media/agarose into
sterile tube; add
desired amount of
cell s

Vortex briefly

cells in tissue culturetreated with trypsin and
EDTA to detach; washed with
serum-free media

total number of colonies per plate was determined by counting the number of colonies
in three distinct 40X magnification fields, averaging the results, and multiplying by
35.5, which equaled the number of 40X magnification fields per plate. Only colonies
greater than 0.5 mm in diameter were counted.
Tumor Growth in Athymic ('Nude') Mice:
Tumor cells were injected into 3-6 week old nude mice to assess tumorigenicity
as described by Rutka, et al (1987):
Cultured glioma cells were harvested by adding 5 ml of Puck’s saline/1 mM
EDTA and 0.5 ml of 0.05pg/ml trypsin to each of 6 confluent T150 flasks. The cells
were pooled in a 50 ml sterile Falcon tube and centrifuged for 4 minutes at 1300 rpm.
The supernatant was aspirated off and the pellet washed by resuspension in 30 ml
RPMI 1640, centrifugation, and aspiration of the supernatant. The cell pellet was
resuspended in 20 ml of RPMI 1640 medium and the concentration determined by
counting with a hemocytometer as previously described. Once the concentration in 20
ml was known, the cell suspension was divided into aliquots containing the required
amount of cells for injecting a total of 4 animals with a desired inoculum of glioma
cells. The aliquots were pelletted by centrifugation and resuspended in 1.2 ml of
phosphate buffered saline (PBS). Each mouse was then injected subcutaneously with
0.3 ml of the cell suspension in the flank with a #25-gauge needle. Control mice were
injected with 0.3 ml PBS alone. Tumor growth was assessed by measuring palpable
subcutaneous tumors in their widest dimension.
Preparation of Plasmid DNA:
Plasmid DNA was prepared by a modified alkaline lysis method as described
by Maniatis et al. (1982).
5 ml of LB medium was inoculated with cells containing the desired plasmid
and grown for at least 8 hours in a shaking 37°C bacterial incubator. If a large quantity
of plasmid DNA was required, 100 pi of this culture was used to inoculate 100-500 ml
of LB medium and a large scale DNA preparation was done as follows:
The bacterial cells were pelletted by centrifugation at 5000 rpm for 10 minutes.
The pellet was resuspended in 10 ml of a sterile (filtered) solution containing 50 mM
glucose, 25 mM Tris-CI (pH 8.0) and 10 mM EDTA. This was transferred to a Beckman
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SW27 tube and allowed to stand at room temperature for 5 minutes. 20 ml of freshly
prepared 0.2 N NaOH/1% SDS was then added. The contents were then mixed by
gentle inversion, and the tube was placed on ice for 10 minutes. 15 ml of cold (4°C)
potassium acetate solution (pH 4.8) was then added. (This solution was prepared by
combining 60 ml of 5 M potassium acetate with 11.5 ml of glacial acetic acid and 28.2
ml water. ) This was then placed on ice for 10 minutes. The tube was then centrifuged
at 20,000 rpm for 20 minutes at 4°C. The supernatant containing plasmid DNA was
then transferred in equal quantities to two 30 ml Corex tubes, and 0.6 volumes of
isopropanol was added to each. This was mixed well and allowed to stand at room
temperature for 15 minutes. The plasmid DNA was recovered by centrifugation in a
Sorvall rotor at 12,000(7 for 30 minutes at room temperature. The resultant pellet was
then washed with 70% ethanol at room temperature and dried briefly in a vacuum
desiccator. The pellet was then dissolved in 5-8 ml TE buffer (0.01 M Tris-CI/0.001 M
EDTA pH 8.0).
Purification of the plasmid DNA, if necessary, was done by centrifugation to
equilibrium in a cesium chloride-ethidium bromide density gradient. For every ml of
DNA solution, 1 g of solid cesium chloride was added to it. The solution was then
mixed by gentle inversion until the salt was completely dissolved. To this was added
0.8 ml of ethidium bromide solution ( 10 mg/ml in water) for every 10 ml cesium
chloride solution. The final density of the solution was 1.55 g/ml as determined by a
refractometer, with adjustments made by adding CsCI or TE buffer as necessary. The
CsCI solution was then transferred to a heat-sealable tube suitable for a Beckman
Type-50 or Type-65 rotor and the remainder of the tube filled with light paraffin oil. The
tube was sealed and centrifuged at 45,000 rpm for 36 hours at 20°C.
Of the several bands of DNA visible, the bottom band representing closed
circular plasmid DNA was removed by piercing the tube with a #21-gauge hypodermic
needle attached to a syringe. The DNA band was drawn into the syringe, and the
remainder of the CsCI solution and paraffin oil was discarded into the appropriate
waste containers.
The ethidium bromide was removed by first adding an equal volume of 1butanol saturated with isoamyl alcohol and mixing the phases vigorously by pipetting.
After centrifuging at 1500(7 for 3 minutes at room temperature, the lower aqueous
phase was transferred to a clean tube and the extraction repeated 5 times until the
solution was cleared of its pink color. The solution was then dialyzed against several
changes of TE (pH 8.0) at 4°C and stored in microcentrifuge tubes at 4°C.
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For screening multiple transformants for the desired plasmid construct, rapid
plasmid preparation was done by the following method derived from Maniatis et al.
(1982):
A 5 ml culture of the transformed bacteria was grown overnight in a bacterial
shaker. The following day, the culture was pipetted into microcentrifuge tubes in 1.5
ml aliquots. The bacteria was pelletted by centrifugation for 1 minute in a
microcentrifuge, and the medium carefully decanted. The pellets were then
resuspended by vortexing in 100 pi of cold (4°C) 50 mM glucose, 10 mM EDTA, and
25 mM Tris-CI (pH 8.0) To this was added 200 mL of freshly prepared 0.2N NaOH, 1%
SDS. The contents of the tubes were mixed by gentle inversion, and the tubes were
immediately stored on ice for 5 minutes.
150 pi of cold (4°C) potassium acetate solution (made as previously described)
was then added to each tube. The tubes were resealed and vortexed gently in an
inverted position for 10 seconds each. Each tube was then immediately stored on ice
for 5 minutes.
After centrifugation for 10 minutes at 4°C, the supernatant from each tube was
transferred to a fresh microcentrifuge tube and extracted with and equal volume of 1:1
phenol/CIA (chloroform/isoamyl acetate 24:1). The tubes were vortexed for 30
seconds and allowed to stand 10 minutes at room temperature. Following
centrifugation for 2 minutes, the aqueous layer was transferred to fresh tubes.
1 ml of 95% ethanol was added to each tube, vortexed, and allowed to stand at
room temperature for two minutes to precipitate the DNA. The DNA was pelletted by
centrifugation for 15 minutes. The supernatant was carefully decanted without
disturbing the pellet, and the tubes were placed inverted on a paper towel to allow all
the liquid to drain. The pellet was then washed of salt by adding 1 ml of 70% ethanol,
vortexing briefly, and centrifuging at 4°C for 10 minutes. The ethanol was carefully
decanted, and the DNA pellet was dried in a Savant Speed-Vac Concentrator.
After drying, the DNA pellets were resuspended in 20 pi of TE buffer with the
addition of T1 RNase to a concentration of Ipg/ml. These preparations could then be
stored at -20°C for extended periods.
Restriction Endonuclease Digests:
Restriction endonuclease digestion was carried out in a buffered salt solution
appropriate for each enzyme as suggested by the enzyme manufacturer. These
buffers were obtained from the manufacturer as 10X solutions and diluted to IX in the
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reaction mixture. The DNA to be digested was placed in the buffered salt solution with
an appropriate amount of restriction endonuclease to assure complete digestion. This
was carried out in a polypropylene microcentrifuge tube placed in a water bath of the
recommended temperature for at least two hours.
Analysis of DNA Fragments - Gel Electrophoresis:
DNA fragments resulting from restriction endonuclease digestion were
analyzed by electrophoresis in 0.85% agarose gels. Gels were made by adding 0.85
g of agarose to 100 ml of TAE buffer ( 40 mM Tris-acetate pH 8.0, 5 mM sodium
acetate, 1 mM EDTA free acid) with the addition of pg/ml of ethidium bromide. The
agarose was melted by heating in a microwave oven, then poured into a horizontal gel
form and allowed to harden. Electrophoresis was performed on a horizontal
apparatus in TAE buffer. A typical electrophoresis was done at a constant voltage of
40V to 55V for one to two hours depending upon the size of the fragments. DNA
fragments were viewed by ethidium bromide fluorescence on an ultraviolet light box.
Isolation of DNA Fragments Using Low Melting Point Agarose Gels:
DNA fragments were isolated from low melting point agarose gels in the
following manner:
50 ml of 0.85% low melting point agarose in TAE buffer with 0.5 pg/ml ethidium
bromide was poured into a horizontal gel form and allowed to harden. The gel was
placed in TAE buffer in an electrophoresis apparatus in a 4°C cold room and the
desired cut plasmid DNA was loaded. A Hindi 11 cut lambda phage DNA standard was
also electrophoresed to assess fragment sizes, but this was loaded several lanes
away from the plasmid DNA to reduce the possibility of contamination when removing
the DNA fragment. After gel electrophoresis at a constant voltage of 40-55V until
fragments resolved, gel was carefully placed on a low wavelength UV lightbox and
the fragment was removed by cutting it out with a razor blade. As little of the
surrounding gel was taken as possible. The gel fragment containing the desired DNA
was then placed in a polypropylene centrifuge tube and incubated in a 68°C water
bath for 5 minutes.
Once melted, the volume was determined by drawing into a pipet, and an equal
volume of high salt buffer (1 M NaCI, 40 mM Tris pH 7.4, 10 mM EDTA) was added.
The tube was then incubated at 68°C for an additional 5 minutes.
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The content of the tube was then extracted once with phenol, leaving the
interface between layers, then two additional times until the interface was gone. The
solution was then extracted with 24:1 chloroform/ isoamyl acetate once, and then the
appropriate amount of 1 M MgCl2 was added to bring the concentration in the solution
to 10 mM. The DNA was precipitated by adding 2 volumes of cold (-20°C) 95%
ethanol and placing on dry ice until frozen. The DNA was pelletted by centrifugation in
a Sorvall centrifuge at 0°C for 30 minutes at 10,000 rpm. The supernatant was
removed, and the pellet washed by adding 1 ml of 80% ethanol, vortexing briefly, then
recentrifuging. The ethanol was carefully poured off and the pellet dried by placing the
tube, its top covered with parafilm in which several small holes were punched, in a
vacuum desiccator. The dried pellet was dissolved in TE buffer, and the DNA
concentration determined by measuring its absorbance at 280 nm.
Ligation of DNA Fragments:
Ligations were typically done in volumes of IQ-IOOpl using T4 DNA and 10 x
ligation buffer containing ATP as supplied by the manufacturer. Most ligations were
performed overnight at 4°C or at room temperature for two hours. Generally, 3 Weiss
units of ligase were used for everyl pg of DNA ligated.
Conversion of DNA with Protruding 3’ Ends to Blunt Ends:
The conversion of protruding 3’ ends to blunt ends was accomplished with the
3’ exonuclease activity of T4 DNA polymerase.
The exonuclease reaction mixture contained approximately 0.5pg of DNA with a
3’ overhang, 2 units of T4 polymerase (Bethesda Research Laboratories), 2 pi of 5X
reaction buffer (supplied by manufacturer), and was carried out in a total volume of 10
pi. The reaction was incubated at 37°C for 5 minutes, then placed on ice.
To resynthesize any DNA bases digested beyond the S’ terminus of the
complement strand, 5 pmol of each of the four deoxyribonucleotides (2.5 pi of a 2 mM
solution of each) were added to the reaction mixture, along with an additional 3 pi of
the reaction buffer and 2 pi of water, for a total reaction volume of 25 pi. This was
incubated at 37°C for 25 minutes. Following this, the volume was increased to 100 pi
with water, the reaction extracted with 1:1 phenol/CIA, and the DNA precipitated with
ethanol as previously described.
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Transformation of Plasmid DNA:
(i) Competent cells were either supplied by the manufacturer (Invitrogen) or
made by the following procedure derived from Maniatis et al. (1982):
A 5 ml overnight culture of the desired strain was grown in LB medium. The
following day, 100 ml of LB medium was inoculated with 0.2 ml of the overnight culture
and incubated in a 37°C shaking incubator until it reached an OD550 of 0.75-0.90.
The cells were then pelletted in cold sterile centrifuge tubes at 4°C for 10 minutes at
10,000#
After careful removal of the medium, the cell pellets were resuspended in a total
of 40 ml of a cold (4°C) sterile solution of 50 mM CaCl2/50 mM KCI. This was kept on
ice for 15 minutes, then centrifuged at 4°C for 10 minutes at 10,0000. Keeping the
cells cold, the supernatant was decanted, and the cells were resuspended in 10 ml of
a cold (4°C) solution of 50 mM CaCl2/ 15% glycerol and immediately frozen at -70°C
in 1 ml aliquots in sterile microcentrifuge tubes.
(ii) Transformation of plasmid DNA into competent cells was performed either
by electroporation based on a protocol developed for BioRad, or by heat shock as
described by Maniatis (1982).
(a) To transform with the electroporation method, it was necessary to
keep all materials (i.e. cuvette, cuvette holder) on ice during the the procedure.
Competent cells were thawed on ice, after which 2 pi of DNA (approximately 0.05 pg in
water) was added to 40 pi of cells. The cells were then allowed to sit on ice for 2
minutes, and then pipetted into a 0.2 cm cuvette. The cells were then shocked in the
electroporation apparatus at 25 pF, 800 ohms, 2.5 kEV with a time constant of
approximately 20. Immediately after electroporation, 1 ml of SOC medium was added
to the cuvette and mixed by pipetting up and down. The cells were pipetted into sterile
microcentrifuge tubes and incubated at 37°C for one hour with shaking. Following
this, 100 pi and 100 pi of a 1:20 dilution of the cells were plated on LB agar plates
containing the appropriate antibiotic selection for the vector. The plates were then
incubated at 37°C overnight.
(b) To transform competent cells by heat shock, 40 pi of competent cells
were diluted to 400 pi with ice cold 50 mM CaCl2 and divided into 100 ml aliquots in
sterile microcentrifuge tubes. Using 100 pi of diluted cells per transformation, 3 pi of
DNA (approximately 0.05 pg, either directly from a ligation reaction or plasmid DNA)
was added, and the cells were incubated on ice for 30-40 minutes. The cells were
then heat shocked by incubating for 2 minutes at 42°C. 1 ml of LB was added, and the
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cells were incubated at 37°C for 1 hour with shaking. 50 pi, 100 pi, and 200 pi of the
transformed cells were plated on LB agar plates containing the appropriate antibiotic
selection and incubated overnight at 37°C.
RNA Isolation From Cultured Cells:
RNA was isolated from cultured glioma cell lines by ultracentrifugation through
a cesium chloride cushion as described by Chirgwin et al. (1979).
Nine T150 flasks of the desired cell line were grown to confluency and the cells
detached by pipetting 5 ml 0.05 pg/ml trypsin into the first flask, allowing the cells to
detach, then transferring the trypsin/cell suspension to the next flask. This was
repeated until all the cells were detached and consolidated into one flask. A
guanidium thiocynate solution was prepared: 4 M guanidium thiocynate [Fluka], 25
mM NaCitrate, 0.5% Na-lauryl sarcosine, adjust pH to 7.0, filter through 0.45 pm filter,
store in dark at room temperature and add 2-mercaptoethanol to a final concentration
of 0.1 M immediately before use. Ten ml of this was added to the suspended cells,
and the resulting viscous solution mixed well by inverting the flask. The contents were
then transferred to a RNase-free blue cap Falcon tube, and could be stored overnight
at 4°C if necessary.
Four to six 10 ml RNase-free Corex tubes suitable for use in a Beckman
SW50.1 rotor were one-quarter filled with a cesium chloride cushion (5.7 M CsCI, 0.1
M EDTA, filter through a 0.45 pm filter), and the guanidium thiocynate solution was
carefully layered on top without disturbing the cushion. The tubes were balanced, and
then centrifuged for 12 hours at 36,000 rpm in a SW50.1 rotor at 20°C. (The rotor had
been allowed to come to equilibrium at 20°C prior to centrifugation). Following
centrifugation, the tubes were carefully removed without disturbing the layers, and the
guanidium thiocynate layer was removed by aspiration into a reservoir via a glass
pipet attached to a hose. A fresh RNase-free glass pipet was connected to the hose,
and taking care not to touch the sides of the Corex tube, the cesium chloride was
aspirated without disturbing the RNA pellet. The top four-fifths of the tube was cut off
with a razor blade, and the pellet was washed in the truncated tube by the addition of
100 pi of 70% ethanol. This was repeated two additional times, with the supernatant
removed by pipetting. The truncated tubes were then placed inverted on a paper
towel to allow all of the fluid to drain. Taking care to avoid touching the side or top of
the tube with the pipet tip, the pellet was then dissolved in 100 pi of RNase-free
(autoclaved) distilled water. The concentration of the RNA was determined by
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absorbance at a 260 nm wavelength. The ratio of absorbance of 260 nm/280 nm was
calculated to determine protein contamination, with acceptable values being >1.7.
Agarose Gel Electrophoresis - RNA
To make a 1% agarose gel for electrophoresis of RNA, 0.75 g of agarose was
added to 54.1 ml of distilled water and 7.5 ml 10X MOPS buffer (0.2 M MOPS, 50 mM
NaOAc, 10 mM EDTA, pH adjusted to 7.0 with NaOH, solution filtered and stored at
4°C in a dark bottle). The mixture was boiled by heating in a microwave oven until all
agarose crystals were in solution, and allowed cool in a 65°C water bath. To this was
added 13.4 ml of 12.3 M formaldehyde (39%) and 7.5 pi of 10 mg/ml ethidium
bromide. The solution was mixed by swirling and quickly poured into a gel form. After
the gel hardened, it was chilled at 4°C for approximately 15 minutes to facilitate the
removal of the gel comb. (To determine the integrity of the wells, lOpI of IX
bromphenol blue dye was loaded into each well and allowed to electrophorese into
the body of the gel.)
RNA samples were prepared in 10 pi aliquots in microcentrifuge tubes by
combining 1.6 pi 12.3 M formaldehyde, 4 pi formamide, 1.2 pi 10X MOPS buffer, 0.5pl
10 mg/ml ethidium bromide, and 2.7 pi RNA in water. The samples were heated for 5
minutes at 65°C, then chilled on ice briefly. After the addition of 1.1 pi of 10X
bromphenol blue dye, the samples were centrifuged briefly to collect all of the solution
at the bottom of the tube and facilitate pipetting. The gel was submerged IX MOPS
buffer in an electrophoresis apparatus and the samples loaded into the wells by
pipetting. The gel was then run at 60 volts for 4 hours with a peristaltic pump
circulating the buffer slowly from the reservoir at the positive pole to that of the
negative pole. ( The pump was started after the samples had run into the body of the
gel.) The gel was analyzed by ethidium bromide fluorescence on a UV light box).
Northern Blots of RNA Gels:
Northern blots of RNA were performed as described by Maniatis et al. (1982)
with some modifications.
RNA was isolated and run on an agarose gel as previously described, loading
30 pg of RNA in each well. A sheet of blotting paper was placed on an inverted gel
form inside a plastic tray to contain the liquid. The blotting paper was then wetted with
10X SSC buffer (1.5 M NaCI, 0.15 M sodium citrate, 5 mM disodium EDTA, pH 7.2),
26

and any bubbles forming between the gel form and the paper were pressed out. ( This
forms the "wick".) After taking a picture of the gel with a ruler at the side margin for
reference, the gel was placed upside down on top of the wick, and the upper right
corner was cut off to provide a reference of orientation. A sheet of nylon filter paper
was soaked in water then 10X SSC briefly, and placed over the gel, matching the
edges of the gel and paper exactly. The right corner of the paper was cut off to
correspond with that removed from the gel.
Three sheets of 3 M Whatman paper (trimmed to the same dimensions as the
gel) were then placed on top of the nylon filter. On top of this was placed a stack
(about ten inches) of blotting paper. The tray was filled with 10X SSC, and the entire
blotting stack was covered with Saran wrap. A large book was then placed on top of
the stack as a weight, and the gel was allowed to blot at room temperature overnight.
The following day, the stack was disassembled, and the nylon paper (now blotted) was
placed into a tray containing 6X SSC (dilute 150 ml 10X SSC to 1 liter with distilled
water), and shook on a rocker for 3 minutes. The filter was then dried in an 80°C oven
for 2 hours.
The filter was prehybidized for 1 hour by sealing the filter in a bag (Seal-a meal)
containing 5 ml prehybridization solution ( 3 ml 10X SSC, 0.5 ml 100X Denhardt’s
solution [2% bovine serum albumin, 2% polyvinyl-pyrrolidone 360, 2% Ficoll 400,
stored at 4°C], 0.1 ml 10% SDS (in water), 2.9 ml distilled water). The bag was
incubated at 67°C with gentle agitation.
The filter was then washed by immersion in 6X SSC for 5 minutes at room
temperature, and placed into a fresh sealable bag containing 100 pi of probe
(approximately 10 million cpm, see method below). This was allowed to hybridize
overnight with gentle agitation at 65°C (high stringency conditions).
The following day the hybridized filter was removed from the bag and washed
for five minutes in 50 ml of 6X SSC solution three times. (The probe and all filter
washes were discarded in the appropriate radioactive waste container.) The filter was
allowed to dry on 3 M Whatman paper, and was analyzed radiographically by
exposure of x-ray film to the radioactive filter using intensifying screens for 5-7 days at
-20°C.
32P Labelling of DNA Probes - Nick Translation:
Nick translation of DNA probes was performed in 25 pi volumes at 15°C.
Reactions were begun with 0.25 pg of the DNA to be labelled, 12.5 units of E. coli
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DNA polymerase I, 5 pi of 5X reaction buffer (supplied by enzyme manufacturer), 1 nM
each of unlabelled dATP, dTTP, dGTP, and 38 mCi of [a-32P] dCTP (6000 Ci/mM).
After incubation for 1 hour, the reaction was stopped with the addition of 1 pi of 0.5 M
EDTA.
The separation of labelled probes from any remaining free nucleotides was
achieved by using Pharmacia "nick columns". The columns were stored at 4°C. Prior
to use, the storage buffer in the column was discarded, and the column was
equilibrated by running 3 mi of TE buffer through it at room temperature. The column
was then loaded with the labelling mixture (up to 100 ml) with the additional loading of
400 pi of TE buffer. The effluent was collected and discarded (contained little or no
radioactivity). An additional 400 pi of TE buffer was loaded, and the effluent
(containing the labelled probe) was saved.
To determine the specific activity of the probe, 5 pi of a 1:100 dilution of the
probe was spotted onto a glass fiber filter and submerged in a solution of 10%
trich loro acetate (TCA)/1% Na pyrophosphate. The filter was then washed 3 times with
5% TCA, and 2 times with 70% ethanol. The filter was dried and counted in liquid
scintillation fluid.
Creation of a cDNA Library:
The following series of protocols for constructing a cDNA library were derived
from the laboratory of A. Arruffo and B. Seed of Massachusetts General Hospital, with
some minor modifications made by Sharon Plon.
Isolation of Messenger ('poly-A') RNA:
Isolation of poly-A RNA was performed by affinity chromatography on an oligodeoxythymidine (oligo-dT) cellulose (invitrogen) column. All materials used were
RNase free. For each mg of RNA to be run through the column, 0.3 ml of packed
cellulose was required. 1 ml siliconized syringes were used as columns, and were
prepared in the following manner:
The column was initially prepared by placing a GF/C filter at the bottom and
washing through 5 M NaOH and rinsing with RNase free water. The appropriate
amount of dry oligo-dT cellulose (0.3 ml dry volume/ mg RNA) was measured and
placed into an RNase free microcentrifuge tube, and 1 ml of 0.1 M NaOH was added.
After equilibration for three minutes, the appropriate amount was poured into the
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column to achieve the desired bed volume. The column was then rinsed with water
until the pH of the eluate was neutral. The column was then rinsed with 2-3 ml loading
buffer ( 0.5 M LiCI 2 mM EDTA, 0.1% SDS, 10 mM Tris-Cl pH 7.5). The resin was then
poured into a 15 ml blue cap Falcon tube (discarding the GF/C filter).
The total RNA (in water) to be run through the column was heated to 70°C for 23 minutes, and enough 2 M LiCI was added to make a final concentration of 0.5 M.
The RNA was then added to the resin in the blue cap tube and agitated on a rocker for
10 minutes to allow the poly-A RNA to bind. The mixture was then pipetted into the
column (new filter in place), and the buffer was allowed to elute. 3 ml of loading buffer
was then run through, followed by 3 mi of middle wash buffer (0.15 M LiCI, 2 mM
EDTA, 0.1 SDS, 10 mM Tris-Cl pH 7.5). The column was allowed to run dry, collecting
the eluate in 100 pi aliquots. The absorbance at 260 nm of the last 300 pi of eluate
was checked, and if it was >0.025, the column was washed with another 1-2 ml middle
wash buffer.
A sterile Q-tip was wet with water, and the top of the column was wiped clean
above the line of the resin. Poly-A RNA was then eluted into a SW50 tube with 1.5 ml
elution buffer (2 mM EDTA, 0.1% SDS). To this was added 150 pi 3 M NaOAc, and the
remainder of the tube was filled to the top with 95% ethanol. The tube was covered
with parafilm, its contents mixed, and then placed at -20°C overnight.
The poly-A RNA was recovered the following day by centrifuging at 50,000 rpm
for 30 minutes. The pellet was resuspended in 50-100 pi water. To determine the
concentration, 2pl was diluted with water to a volume of 200 pi and its absorbance at
260 nm was measured. To ensure that the RNA had not degraded, 1 pg was run on
an agarose ge! and a band corresponding to poly-A RNA was visualized. (Degraded
RNA would have no bands visible.)
cDNA Synthesis:
For this method of synthesizing cDNA, the first strand of DNA is synthesized
from the RNA template using reverse transcriptase priming from the poly-A tail with an
oligo-dT primer. The second strand is synthesized using DNA polymerase I and
RNase H.
In a siliconized microcentrifuge tube, 3-5 pg of poly-A RNA (in water) was
heated to 100°C for 30 seconds and quenched on ice. The volume was then adjusted
to 70 pi with water. To this was added 20 pi RT1 buffer ( 0.25 M Tris-Cl pH 8.8, 0.25 M
KCI, 30 mM MgCI2), 2 pi RNase inhibitor (Promega or BMB), 5 pg of oligo dT primer
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(Collaborative Research), 2 pi each of a 25 mM solution of dATP, dGTP, dTTP, dCTP
(Pharmacia or USL Biochemicals), and 1 pi 1 M DTT. 100 units of reverse
transcriptase (Seikagu-American XL grade) was added and the reaction was
incubated at 42°C for 1 hour. Following this, the reaction was heated at 70°C for 10
minutes to inactivate the RNase inhibitor and the reverse transcriptase.
To begin synthesis of the second strand, the above reaction mixture was
diluted with 320 pi water. To this was added 80 pi of RT2 buffer ( 0.1 M Tris-CI pH 7.5,
25 mM MgCI2, 0.5 M KCI, 0.25 mg/ml bovine serum albumin [acetylated and nuclease
free], 50 mM DTT), 5pl DNA Polymerase 1 (BMB, 5 units/pl), and 2 pi RNAse H
(Bethesda Research Laboratories, 2 units/pl). The reaction mixture was incubated at
15°C for 1 hour, then at 22°C for 1 hour. Following this, 20 pi of 0.5 M EDTA was
added, and the reaction mixture was extracted with 1:1 phenol/C!A.

10 pg of linear

acrylamide, 50 pi of 5 M NaCI and 1 ml of ethanol was added to the aqueous phase.
The solution was mixed well, the centrifuged at room temperature for 4 minutes. The
solution was then vortexed briefly and centrifuged again for another 2 minutes. The
supernatant was then carefully removed, and 1 ml of 70% ethanol was added to wash
the pellet. The pellet was centrifuged again and all traces of ethanol were removed.
The pellet was not dried.
Size Fractionation of cDNA:
Size fractionation of cDNA was performed via migration on a potassium acetate
linear gradient. Using a stock solution of 40% KOAc (filtered), four solutions were
made: all were 2 mM EDTA, Ipg/mS ethidium bromide, and 20%, 15%, 10%, and 5%
KOAc, respectively. In a SW50 polyallomer tube, 1.2 ml of each solution was carefully
layered, starting with the 20% KOAc solution on the bottom and ending with the 5%
KOAc solution. This was done slowly to avoid excess mixing. The cDNA mixture was
pipetted on top of the gradient, and the tube centrifuged for 3 hours at 50,000 rpm.
The fractions were collected in siliconized microcentrifuge tubes by piercing the
gradient tube near the bottom with a #25-gauge butterfly needle (with attached tubing
and a clamp to stop flow if necessary). Three 0.5 mi fractions, then nine 0.25 ml
fractions were collected, and the remainder discarded. To each of the samples was
added 5 pg linear acrylamide and enough ethanol to fill the tube. The samples were
chilled at -20°C overnight, then centrifuged for 10 minutes. The supernatant was
removed, and the pellets were each rinsed with 1 ml 70 % ethanol. The samples were
centrifuged again for 10 minutes, and all traces of the ethanol removed. Without
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drying the pellet, each was resuspended in 20 pi TE buffer. 2 pi of each fraction was
run on a 0.7% (RNA) agarose gel with size markers, and the fractions having the
desired sizes were pooled.
Plasmid Vectors and Bacterial Strains:
The plasmid used for creating a cDNA library was pCDM8 (Invitrogen), modified
for this project by insertion of a Not I linker at position 1179 (Sacll site). This is a 4.5
kilobase versatile eukaryotic expression vector that contains a CMV promoter and
enhancer, a polyadenylation signal and splice segment, an SV40 and polyoma
eukaryoric origin of replication , an Ml3 origin for single strand rescue, an piVX (Col
El like) high copy plasmid origin, and a T7 promoter for RNA transcription. As a
selectable marker, it also contains a SupF gene (tRNA amber suppressor gene) for
use with strains carrying amber antibiotic resistance genes. Constructs made with
pCDM8-Not I were transformed into competent MC1061/P3 cells [AraD139, A(ara, leu)
7696, galll, galK, AlakY74, hsr-, hsrm+, strA {p3 amber ampr, tetr, Kmr}]. This strain
contains a large plasmid (p3) which contains antibiotic (ampicillin, tetracycline, and
kanamycin) resistance genes with amber mutations. When this strain was transformed
with a plasmid containing the SupF gene (e.g. pCDM8-Not I), the amber mutations in
the p3 antibiotic resistance genes were suppressed. Transformants were then
selected by growth on solid medium containing 20 pg/ml ampicillin and 7.5 pg/ml
tetracycline. (See Figure 3.)
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FIGURE 3
Partial restriction enzyme map of modified cDNA library vector pCDM8-Notl .
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RESULTS

Characterization of Cell Lines - Clonigenicity:
The glioma cell lines studied were screened initially for clonigenicity by
suspension in semi-solid agar medium supplemented with 10% fetal calf serum (low
stringency conditions). For each cell line, cells were plated at four concentrations: 1000
cells/plate, 2000 cells/plate, 4000 cells/plate, and 8000 cells/plate. For each experiment,
the plating was done in triplicate and the colonies were allowed to grow for 17 days.
Cell line U373mg was eliminated from the study due to apparent contamination of the
frozen stock.
Of the remaining cell lines, U251mg-NIH exhibited a high level of clonigenicity
under these low stringency conditions, with virtually 100% of plated cells forming
colonies at all plating concentrations. Cell line U343mgA-SF was also clonigenic under
these conditions, with cloning percentages ranging from 33.1% to 47.9% of cells plated
(mean=38.9%). Cell line U118MG was moderately clonigenic under these conditions,
with cloning percentages ranging from 8.0%-13.2% of cells plated (mean=10.6%).
Cell lines U105mg and U251mg-SF exhibited little, if any, ability to clone in soft
agar in low stringency conditions. Cell line U105mg had detectable colonies only when
plating at concentrations of 4000 cells/plate or greater, with cloning percentages
ranging from 0% to 3.0% of cell plated (mean=0.75%). Cell line U251mg-SF had
cloning percentages ranging from 4.7% to 6.0% of cells plated (mean=5.6%).
Soft agar cloning experiments were repeated with the two most clonigenic cell
lines (U251mg-NIH and U343mgA-SF) and the two least clonigenic cell lines (U105mg
and U251mg-NIH) under high stringency conditions (semi-solid medium supplemented
with only 2% fetal calf serum). The colonies were allowed to grow for 20 days. Under
these conditions, cell line U251mg-NIH remained clonigenic, but the level of
clonigenicity was dependent upon the number of cells plated. U251mg-NIH was
virtually 100% clonigenic under these conditions with plating concentrations of 1000
cells/plate and 2000 cells/ plate, but at concentrations of 4000 cells/plate and 8000
cells/plate the cloning percentages dropped to 66.0% and 68.2% of cells plated,
respectively.
Cell line U343mgA-SF unexpectedly exhibited increased clonigenicity under
high stringency conditions. Cloning percentages ranged from 78.7% to 97.8% of cells
plated (mean=88.7%). This was a statistically significant change (see Graph 1).
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GRAPH 1
Graph comparing clonigenicity of cell line U343mgA-SF in soft agar
supplemented with 2 % fetal calf serum versus 10 % fetal calf serum. The p values
reported were obtained using an unpaired two-tailed t-test.
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Cell lines U251mg-SF and U105mg, which had exhibited minimal clonigenicity
under low stringency conditions, each had a cloning percentage of 0% under conditions
of 2% fetal calf serum supplementation. (See Table 2 and Figures 4-7.)
Characterization of Cell Lines - Tumorigenicity:
To establish the correlation between a cell line’s ability to clone in soft agar and
form tumors in athymic "nude" mice, cell lines U251mg-NIH and U343mgA-SF
(clonigenic), as well as cell lines U105mg and U251mg-SF (non-clonigenic) were
suspended in phosphate buffered saline and injected subcutaneously into these
animals. Four experimental sets of 3 to 5 animals were injected with approximately 1
X107 cells from each cell line per set. Any additional experiments injecting other total
cell numbers were dependent upon the availability of the cells and the mice.
Due to its relatively short doubling time and dense growth in a monolayer,
enough cells were harvested from cell line U343mgA-SF to study the results of five
different cell inoculums: 1X106, 5X106, 1.25X107,5X107, and 7.5X107. With the
exception of the inoculum of 1X106, each of the cell inoculums produced tumors of at
least 0.5 cm in diameter in all mice, with the establishment of a hard, palpable tumor
mass within one week of injection. Tumors persisted for the life of the animal. The
inoculum of 1XI06 cells did not produce tumors in any of the experimental animals.
Cell Sine U251mg-NIH also produced in all experimental animals tumors of at
least 0.5 cm in diameter when injected with a total cell inoculum of 1X107 cells. An
inoculum of 5X106 cells produced 1 cm tumors in 2 of 4 experimental animals by one
week, with the remaining two animals forming tumors 0.3 cm and 0.4 cm in diameter
by 30 days. An inoculum of 1X106 was also injected into each of four experimental
animals, but failed to produce tumors in any.
Cell line U105mg produced tumors in each of the three animals injected with an
inoculum of 1.1X107. These tumors reached approximately 0.75 cm in diameter by
one week, but then regressed such that there was no visual or palpable evidence of
the tumor by 15 days. The animals were studied for a total of 52 days, and there was
no evidence of tumor recurrence at the injection site.
Cell line U251mg-SF was injected into four animals at an inoculum of
1.25X107. One of the four mice had a firm swelling of approximately 0.5 cm at the
injection site by one week, but this regressed completely by the second week. These
mice were studied for a total of 54 days and had no evidence of tumor formation at the
37

TABLE 2

Results of soft agar cloning experiments.
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TABLE 2

Clonigenicity
(% of plated cells forming colonies)
Cell line

2% FCS

10% FCS

U251mg-NIH

66-100%

100%

U343mg-SF

78.8-97.8%

33.1-47.9%

U118mg

8.0-13.2%

U105mg

0%

0-3.0%

U251mg-SF

0%

4.7-6.0%
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FIGURE 4

Clonigenic glioma cell lines U343mgA-SF and U251mg-NIH suspended in sol
agar supplemented with 10% fetal calf serum. Under these conditions, U343mgA-SI
formed colonies from 33.1% to 47.9% of cells plated. Cell line U251mg-NIH formei
colonies from virtually 100% of plated cells.
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CLONIGENIC GLIOMA CELL LINES
10% FETAL CALF SERUM. 0.25% AGAROSE

FIGURE 5
Clonigenic cell lines U343mgA-SF and U251mg-SF suspended in soft agar
supplemented with 2% fetal calf serum. Under these conditions, U343mgA-SF formed
colonies from 78.7% to 97.8% of cells plated. Cell line U251mg-NIH formed colonies
from 66.0% to 100% of cells plated, with clonigenicity decreasing with increasing
numbers of cells plated.
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FIGURE 6
Non-clonigenic cell lines U105mg and U251mg-SF suspended in soft agar
supplemented with 10% fetal calf serum, Under these conditions, U105mg formed
colonies from 0% to 3.0% of cells plated. Cell line U251mg-SF formed colonies from
4.7% to 6.0% of cells plated.

44

c
N)

.

—

cn
3
CQ
|

CO

~n

c:
—*

o
cn
3
to1
1
X
X

FIGURE 7
Non-clonigenic cell lines U105mg and U251mg-SF suspended in soft agar
supplemented with 2 % fetal calf serum. Both cell lines had a clonigenicity of 0%
under these conditions.
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NON-CLONIGENIC GLIOMA CELL LINES
2% FETAL CALF SERUM
0.25% AGAROSE

site of injection. Subcutaneous injections of 0.3 mi of phosphate buffered saline were
performed on three athymic mice as control experiments. These animals did not
produce tumors at the site of these injections. {See Table 3 and Figures 8-16.)
Growth of Non-Clonigenic Cell Lines in Conditioned Media:
Since some growth factors (such as PDGF-A) are actively secreted by cells and
are associated with a cell line’s tumorigenicity and clonigenicity when overexpressed,
culture medium from growing cultures of the two studied clonigenic cell types (i.e.
conditioned medium) was used to suspend non-clonigenic cells in soft agar. If a
growth factor which was associated with the clonigenicity had been excreted into the
medium, it could be possible that exposure of non-clonigenic cell lines to conditioned
medium may induce them to clone. The conditioned medium was obtained by growing
cell cultures of the clonigenic cell lines U343mgA-SF and U251mg-NIFi to 70%
confluency in RPMI 1640 medium with 2% fetal calf serum. The medium was then
replaced with fresh medium of the same type and the cells were incubated for an
additional four days. The medium was then pipetted from the culture flask and
centrifuged for 3 minutes at 1200 rpm to pellet any cultured cells that may have
become suspended. Cell lines U105mg and U251mg-SF were then each suspended
at concentrations of 8000 cells/plate and 4000 ceSIs/plate in soft agar containing equal
parts conditioned medium and RPMI 1640/2% fetal calf serum. A low percentage of
fetal calf serum was used to initially grow the cells and also to suspend them in agar to
reduce the possibility of a contribution of a significant amount of growth factor from the
serum which may inhibit the clonigenic cell line from maximal expression of its growth
factor(s) and/or result in a significant background level of cloning in soft agar.
After incubation for 15 days, neither non-clonigenic cell line demonstrated the
ability to done in soft agar in the presence of 50% conditioned medium from either of
the two clonigenic cell lines. (See Figure 17.)
Modification of pCDM8 Vector - Insertion of a Not! Linker:
Once a correlation between clonigenicity and tumorigenicity had been
established in the cell lines studied, a cDNA library made from the poly-adenyiated
(mRNA) transcripts of the clonigenic/tumorigenic cell lines was to be created and
transfected into non-clonigenic/non-tumorigenic cell lines to determine if they could be
induced to clone in soft agar and form tumors in nude mice. Prior to the creation of
48

TABLE 3

The results of the nude mice studies.
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TABLE 3

Cell line

U343mg-SF

U251mg-NIH

U105mg

U251mg-SF

Clonigenic

+

+

-

Inoculum

# of mice with tumors/
total mice inoculated

1X106 cells

0/4

5X106 cells

4/4

1.25X 107 cells

3/3

5X 107 cells

4/4

7.5X 107 cells

5/5

1X106 cells

0/4

5X106 cells

2/4*

IX 107 cells

4/4

1.1X 107 cells

0/3**

1.25X 107 cells

0 / 4***

*the remaining two animals formed tumors < 0.5 cm in diameter
**3/3 animals formed tumors >0.5 cm which regressed completely by two weeks
***1 / 4 animals formed a tumor >0.5 cm which regressed completely by two weeks
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FIGURE 8
A nude mouse inoculated with 1XI06 cells from clonigenic cell line U251mgNIH. After 35 days, 0 of 4 mice formed tumors at the site of injection. (Top photo: 7
days after inoculation; bottom photo: 15 days after inoculation.)
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FIGURE 9
A nude mouse inoculated with 1x107 cells from clonigenic cell line U251mgNIH. After 47 days 4 of 4 mice formed tumors ranging from 0.7 cm to 0.9 cm in
diameter at the site of injection. (Top photo: 10 days after inoculation; middle photo:
15 days after inoculation; bottom photo: 25 days after inoculation.)
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FIGURE 10
A nude mouse inoculated with IxlO6 cells from clonigenic cell line U343mgASF. Of the 4 animals inoculated, there was 1 death at 38 days (no evidence of tumor
formation), and the remaining 3 animals had no tumor formation at the site of injection
after 43 days. (Top photo: 7 days after inoculation; bottom photo: 15 days after
inoculation.)
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FIGURE 11

A nude mouse inoculated with 5x106 cells from clonigenic cell line U343mgASF. After 43 days, 4 of 4 animals developed tumors ranging from 0.4 cm to 0.9 cm in
diameter at the site of injection. (Top photo: 7 days after inoculation; bottom photo:
15 days after inoculation.)
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FIGURE 12
A nude mouse inoculated with 1.25x107 cells from clonigenic cell line
U343mgA-SF. After 11 days all 3 inoculated animals developed tumors at the site of
injection (2 had tumors 0.5 cm in diameter, 1 had a tumor 1 cm in diameter). After 43
days, one tumor had regressed to 0.2 cm in diameter; the remaining tumors were 0.6
and 0.9 cm in diameter. (Top photo: 7 days after inoculation; middle photo: 21 days
after inoculation; bottom photo: 37 days after inoculation.)
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FIGURE 13
A nude mouse inoculated with 5x107 cells from clonigenic cell line U343mgASF. After 42 days, 4 of 4 mice had developed tumors at the site of injection (3 were
1 cm in diameter, 1 was 0.8 cm in diameter).

(Top photo: 7 days after inoculation;

middle photo: 28 days after inoculation; bottom photo: 37 days after inoculation.)
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FIGURE 14
A nude mouse inoculated with 7.5x107 cells from clonigenic cell line U343mgASF. After 47 days, 5 of 5 mice inoculated developed tumors ranging from 0.7 cm to
1.4 cm in diameter at the site of injection. (Top photo: 7 days after inoculation; middle
photo: 16 days after inoculation; bottom photo: 26 days after inoculation.)
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FIGURE 15
A nude mouse inoculated with 1.25x107 cells from non-clonigenic cell line
U251mg-SF. After 7 days, 1 of 4 mice had evidence tumor formation at the site of
injection; by 14 days this completely regressed. After 54 days, 0 of 4 mice had
evidence of tumor formation at the site of injection. (Top photo: 7 days after
inoculation, with evidence of tumor formation; middle photo: 14 days after
inoculation, no evidence of tumor formation; bottom photo: 33 days after inoculation,
free of tumor.)
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FIGURE 16
A nude mouse inoculated with 1.1x107 cells from non-clonigenic cell line
U105mg. After 7 days, 3 of 3 mice inoculated had developed tumors ranging from
0.7 cm to 1 cm at the site of injection. By 14 days, the tumors completely regressed in
all three animals. By 52 days, 0 of 3 animals had evidence of tumor formation. (Top
photo: 7 days after inoculation, with evidence of tumor formation; middle photo: 15
days after inoculation, tumor completely regressed; bottom photo: 30 days after
inoculation, free of tumor.)
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FIGURE 17

Non-clonigenic cell lines U105mg and U251mg-SF suspended in soft agar
containing 50% conditioned medium from clonigenic cell line U343mgA-SF and 2%
fetal calf serum. Both cell lines failed to clone in soft agar under these conditions.
Identical results were obtained when suspending these cell lines in soft agar
containing 50% conditioned medium from clonigenic cell line U251mg-NIH and 2%
fetal calf serum.
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these cDNA libraries from the clonigenic, tumorigenic cell lines U251mg-NIH and
U343mgA-SF, the plasmid vector pCDM8 was modified to facilitate the future removal
and characterization of the cDNA from the host genome of any transfected cell lines
that ultimately became transformed.
It is possible for a library vector containing cDNA to become incorporated in the
host genome at any random position when transfected. Removal of that cDNA for
future characterization can only be accomplished by restriction enzyme digestion of
the host cell DNA with an enzyme that has recognition sites flanking the cDNA
insertion site in the vector. It would be necessary, however, to do this in such a
manner that would distinguish the cDNA from the digested host cell DNA. This was
achieved by inserting a Notl linker at a site in a region 5’ of the cDNA insertion site. A
Not I site already exists in the 3’ region polylinker. Since the Not I recognition
sequence is eight base pairs in length (GC*GGCCGC), Not I infrequently cleaves
genomic DNA. Any resultant fragments of a Not I digestion of the host genome would
almost exclusively be many orders of magnitude greater in length than a fragment
produced by the excised cDNA. Therefore, the cDNA could be distinguished from the
vast majority host DNA by virtue of fragment length.
A Sacll restriction enzyme recognition site at position 1179 was chosen to insert
the Notl linker since there was only a single recognition site for this enzyme in the
plasmid, thus only one possible site for linker insertion. Additionally, this restriction
site did not interfere with the SupF suppressor gene or the promoter sequence, which
are both in the immediate 5’ region of the cDNA insertion site.
Insertion of the Not I linker was accomplished by digesting 0.5 pg of the pCDM8
with 14 units of Sacll enzyme for 3 1/2 hours to ensure as complete digestion a
digestion as possible. After extracting with phenoLCIA and ethanol precipitating the
cut DNA, the 3’ overhang of the Sacll sites were filled in with T4 DNA polymerase.
Following this, the Not I linker was annealed and ligated to the vector. The ligation
reaction was then phenol extracted, and the DNA ethanol precipitated and cleaved
with Sacll to linearize any plasmid DNA not filled in by the T4 DNA polymerase. After
incubating with 14 units of enzyme for 1 1/2 hours, the DNA was phenol extracted and
ethanol precipitated.
The ligated DNA was then transformed into competent MC1061/P3 cells by the
heat shock method and plated on LB amp/tet plates. Eighteen transformants were
selected and grown in 5 ml overnight cultures. During growth overnight, one tube
became uncapped and the culture was discarded. The DNA from the remaining 17
cultures was isolated by alkaline lysis rapid preparation, and each candidate was
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digested with Not I. Two of the seventeen candidates were found to produce the
desired banding pattern on gel electrophoresis (i.e. two fragments of sizes 3.0 kb and
1.5 kb). One of these was selected (candidate #15), amplified, and purified by cesium
chloride gradient centrifugation. (See Figure 18).
Isolation of RNA From Cell Lines:
RNA was isolated from cell lines U251mg-NIH, U251mg-SF, U343mgA-SF, and
U105mg by the guanidium thiocynate method, and was electrophoresed in an RNA
agarose gel to ensure that no degradation had occurred during preparation.
Northern Blot Analysis of Glioma Cell line RNA:
The RNA from the four glioma cell lines studied was probed with radioactivelylabelled DNA coding for the growth factor PDGF-A to determine if RNA transcripts of
this factor were produced and could be associated with the cell lines’ cloning and
tumor formation characteristics. This growth factor was chosen for it unique
characteristics (see Discussion).
30 pg of RNA from each cell line as well as a positive control (U343mg 02:6)
and a negative control (KNCR) were used for the blot. After hybridization of the probe,
the blot was exposed to radiographic film for four days at -20°C. The autoradiograph
revealed that cell line U343mgA-SF produced a high number of copies of mRNA with
affinity for the PDGF-A probe, and that of cell line U105mg had a moderate number of
mRNA copies with affinity for the PDGF-A probe. RNA from cell lines U251mg-NIH and
U251mg-SF did not bind the probe. (See Figure 19.)
Isolation of 'Poly-A' RNA and Synthesis of cDNA:
RNA from the clonigenic/tumorigenic cell lines U251mg-NIH and U343mgA-SF
was to be used to create a cDNA library. The initial step was the isolation of the poly-A
(messenger RNA) transcripts from the total RNA that had been isolated from each cell
line. This was accomplished by eluting 208 pg of RNA from cell line U251mg-NIH and
368 pg of RNA from cell line U343mgA-SF (80 pi from each sample) through oligo-dT
cellulose columns. 10.4 pg of poly-A RNA (5% of total RNA) was recovered from cell
line U251mg-NIH and 24.4 pg (6.6% of total RNA) was recovered from cell line
U343mgA-SF.
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FIGURE 18
0.85% agarose gel demonstrating the additional Not I site in the modified
pCDM8 vector after insertion of a Not I linker at position 1179:
LANE

1

2

3

4

5

SAMPLE

A phage

pCDM8

pCDM8

pCDM8-Notl

pCDM8-Notl

ENZYME(S)

Hindlll

none

Not 1

none

Not 1

Digestion of pCDM8 with Not I linearizes the plasmid, giving one 4.5 kb band by
agarose gel electrophoresis. Digestion of linker-modified pCDM8-Not I with Not I
produces two fragments, approximately 3.0 and 1.5 kb.
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FIGURE 19
Northern blot analysis of glioma cell line RNA to PDGF-A DNA probe.

Cell line

U343mgA-SF produced a high number of mRNA copies with affinity to the PDGF-A
probe, cell line U105mg had moderate number, and RNA from both cell lines
U251mg-NIH and U251mg-SF had no detectable affinity for the probe.
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cDNA was synthesized from 5 pg of U251mg-NIH and U343mgA-SF poly-A
RNA using a modified Gubler and Hoffman procedure (1983) in which the first strand
of DNA is synthesized with reverse transcriptase with the poly-A RNA as the template.
The RNA of the RNA-DNA hybrid is nicked with RNAse H, and the second strand is
synthesized with E. coli DNA polymerase I which uses the nicked RNA fragments as a
primer (see "Materials and Methods). T4 DNA ligase was used to close any nicks in
the double-stranded cDNA.
Following the synthesis of the cDNA, phosphorylated linkers (included in "The
Librarian I" cDNA library construction system [Invitrogen]), were ligated to the ends of
the cDNA fragments overnight at 15°C. These linkers had a "-CACA" 3’ overhang that
would be compatible with the BstXI insertion site in the pCDM8-Not I vector. Since the
BstXI overhang does not allow more than one linker to be added to each end of the
cDNA strand, restriction endonuclease digestion after the addition of the linkers was
not necessary.
To remove excess linkers from the sample, as well as rid the library of small,
presumably incomplete, cDNA transcripts, the cDNA was centrifuged through a
potassium acetate step gradient. Fractions with an average cDNA length of greater
than 500 bp as determined by migration on an agarose gel were pooled.
Preparation of pCDM8-Notl Vector:
The modified pCDM8 vector, pCDM8-Notl, was prepared for ligation of the
cDNA by removal of the "stuffer" situated between the BstXI restriction sites.
Approximately 20 pg of pCDM8-Notl was digested with a large excess BstXI overnight
at 50°C. The restriction digest mixture was then loaded on a potassium acetate step
gradient, prepared identically as for the cDNA fractionation. Following centrifugation,
the gradient was viewed with a UV light, and the band corresponding to the linearized
vector (at approximately two-thirds of the length of the gradient) was removed with a
syringe, precipitated, and dissolved in TE buffer. (See Figure 20.)
Ligation of cDNA to pCDM8-Notl Vector:
1 pg of the prepared vector was ligated to 0.2 pi, 0.5 pi, 1 pi and 2 pi of the
fractionated cDNA from U251mg-NIH and U343mgA-SF. The ligation was incubated
overnight at 15°C in a volume of 10 pi.
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FIGURE 20
0.85% agarose gel demonstrating pCDM8-Not I vector after removal of BstXI
stuffer fragment and purification on a potassium acetate gradient. (Lane 1: X phage
DNA cut with Hindlll; Lane 2: purified pCDM8-Not I vector minus the BstXI stuffer.)
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DISCUSSION

The initial survey of glioma ceil lines revealed a variety of responses to
suspension in soft agar and proliferation in nude mice. Cell lines U251mg-NIH and
U251mg-SF had completely opposite responses, with the former being tumorigenic
and clonigenic, and the latter having neither of these properties. This is of particular
interest since both these cell lines originated from the same primary cell line derived
from a glioblastoma. This would indicate that these two cell lines have diverged from
each other in vitro during a high number of independent passages in culture. The
parent cell line, U251 MG, has been reported to be tumorigenic in nude mice (Signer,
et al., 1981), suggesting that cell line U251mg-SF may have lost the ability to either
produce or respond to the factor(s) necessary for this property. The failure of
conditioned medium from U251mg-NIH to induce clonigenicity in U251mg-SF could
be interpreted that autocrine stimulation from an endogenously expressed and
excreted growth factor may not be the mechanism for uncontrolled proliferation in this
cell line, or conversely, that U251mg-SF has lost the ability to express the receptor for
such a growth factor. Karyotypic analysis could give further insight to the degree of
divergence of these two related cell Sines.
Another explanation for the observed divergent phenotypic expression of
U251mg-NIH and U251mg-SF despite a common ancestry is that overexpression of
more than one oncogene is necessary for full malignant transformation (i.e.
anchorage-independent growth, low serum requirement, tumorigenicity in nude mice,
etc.) in this cell line. This has been observed in the in vitro transformation of primary
rat embryo fibroblasts which require transfection with both myc and ras genes to
acquire the fully transformed phenotype (Land, et al., 1983). If U251mg-SF no longer
expressed one of multiple genes necessary for full malignant transformation, then it
could be immortal in culture without possesing any of the characteristics of full
malignant transformation. Transfection of U251mg-SF with cDNA derived from
U251mg-NIH mRNA could provide expression of this putative gene and induce
tumorigenicity.
Cell line U343mgA-SF behaved in an unexpected manner when suspended in
soft agar in that it had a significantly higher cloning efficiency in medium
supplemented with 2% fetal calf serum as opposed to the more enriched medium with
10% fetal calf serum supplementation. It is possible that exposure of this cell line to a
low serum environment may stimulate increased production of an endogenous
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mitogenic factor that confers greater clonigenicity. Likewise, it could also be possible
that a low serum environment induces increased expresssion of receptors for a
mitogenic factor. Additionally, it is possible that serum contained a substance
inhibitory to the growth of this cell line.
It is also of interest that U343mgA-SF produced a large number of mRNA copies
which hybridized to the PDGF-A probe. Nister, et al. (1987) have studied the
progression of this cell line through high numbers of passages in vitro and have
concluded that activation of PDGF genes may have been an early event in the
development of this glioma. The failure of cell line U251mg-NIH to produce a high
mRNA copy number with affinity to PDGF-A suggests that while overexpression of
PDGF-A is correlated with tumorigenicity in U343mgA-SF, it is not an explanation for
this property in all glioma cell lines.
In cell lines U251mg-NIH and U343mgA-SF there was complete correlation
between the ability to clone in soft agar and form tumors in nude mice when given a
cell inoculum of 5X106 cells or greater. Cell line U251mg-SF had neither clonigenic
nor tumorigenic properties at comparable cell inoculums. U105mg, a non-clonigenic
cell line, did produce tumors in each of three experimental animals at an inoculum of
1.1X107, but these tumors completely regressed by two weeks. Since a biopsy
sample was not obtained from the tumor prior to its regression, it is uncertain if the
tumors were truly of glial origin, or were a reactive process to inoculation. To argue
against this, no such reaction was observed when non-tumorigenic inoculums of other
cell lines were injected. If the observed tumors were of glial origin, this result suggests
that U105mg may exist in an intermediate catagory of malignant phenotype,
possessing the factor(s) necessary to initally grow as a xenograft in nude mice, but
lacking whatever factor(s) necessary for sustenance of that growth and, perhaps, the
correlated proliferation in soft agar. Future investigation of this cel! line would include
biopsy of tumor tissue and study of a wide spectrum of cell inoculums in nude mice.
The phenotypic diversity displayed by the glioma cell lines under investigation
in this study echos that reported in the literature. Bigner, et al. (1981) reported
heterogeneity of both genotypic and morphologic characteristics in 15 human glioma
cell lines, 10 of which originated from glioblastomas. This heterogeneity included
different tumorigenic properties among cell lines derived from the same histologic
grade tumor. Such a range of phenotypic and genotypic expression points toward the
proposed existence of a complex series of events that lead to malignant progression in
glioma cells (see "Introduction"). This is in contrast to other malignancies which
appear to be associated with specific chromosomal aberrations, such as the
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Philadelphia chromosome 9:22 translocation in chronic myelogenous leukemia
(DeKlein, et al., 1982), or chromosome 13 deletions in the retinoblastoma (Cavenee,
etal., 1985).
The complexity of this system makes it an ideal one to probe for factors related
to tumorigenicity. The approach used in this investigation assumed that a tumorigenic
cell line would synthesize a factor, regulator, or possess a regulatory gene not present
in non-tumorigenic cell lines. Thus, by making a library from its mRNA and transfecting
a non-tumorigenic cell line, it could be possible to introduce that factor into that cell
line and induce tumorigenicity. (The construction of the libraries is the point where this
investigation is at present.) This approach is not without limitations. For example, an
estimated 5% of mRNA transcripts are not poly-adenylated, and therefore would not
be recovered in the oligo-dT selection of mRNA to be used as the template for cDNA.
If the mRNA encoding the activity being sought was in that 5%, then it would be
undetected in this study. Additionally, this study does not account for the possibility
that a chromosomal deletion, or underexpression of a certain factor, or "anti¬
oncogene", could be related to tumorigenicity. This possibility has been raised by Blin,
et al. (1987) regarding the enhanced expression of four cellular oncogenes in a
human glioblastoma cell line with nullisomy 13.
The further study of glioma tumorigenicity, as initiated in this investigation,
would include a survey of other documented factors expressed by gliomas. As
previously discussed (see "Introduction"), it has been well documented that many
gliomas overexpress the EGF receptor. It would be insightful to screen the cell lines
studied in this investigation to determine if there is any correlation between the
expression of this receptor and tumorigenicity. Other interesting studies would include
determining the expression of PDGF-B as well as the PDGF receptor. These studies,
in addition to completion of the cDNA library and transfection of non-tumorigenic cell
lines, may provide insight into the oncogenic process of gliomas and give us further
clues into what appears to be the multistep process of cancer.
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